Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
Atea Pharmaceuticals Inc AVIR
$4.70
▼ -0.84%
($-0.04)
📅 Earnings This Week
Open
$4.74
Prev Close
$4.74
Day Range
$4.69 – $4.98
52W Range
$2.78 – $6.45
Market Cap
$376.13M
Beta
0.27
EPS (TTM)
$-2.12
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-30 |
| Shares Out. | 80,030,000 |
| Website | ateapharma.com/ ↗ |
| Phone | 18572048109 |
| Employees | 55 |
| Net Income | -$45.4M |
| Total Assets | $267.1M |
| Total Liabilities | $33.4M |
| Equity | $233.7M |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Atea Pharmaceuticals Inc is a publicly traded company under the ticker symbol AVIR on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)